Skip to content
Cultural Foundation
Author:
Genelux Corporation
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
September 9, 2026
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13, 2026
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
June 30, 2026
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 7, 2026